It is 23% of the company and the placing price is where the share price was 6 weeks ago so the discount is not that surprising.
It’s clear that Cardon has been wanting to move onto other things since he gave up being CEO in 2018 and then moved to non exec in 2019.
At least the overhang is gone now. |
Secondary placing - Hit share price very hard. Views?
8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021 |
Nice uplift since I bought during the first week of May. Our vet uses ANCR products:when i mentioned the imminent release of a new product, the vet was very interested . Suppliers of products to vets are onto a good thing. |
that video now on ggp share board , a good example for other shares |
The growth in pet ownership over lockdown and owner’s desires to keep their pets fit and healthy has been great news for the pet care sector. However, who are going to be the long-term winners from the current pet boom?
Investor’s Champion’s research highlights some terrific companies which should continue to do well, including a star performer. #ancr #chwy #cvsg #elan #idxx #nesn #pets #zts |
The website identibase is in complete disarray at present, shambolic. Vets, animal charities and private individuals unable to register chips they have paid for.Fraudulent incompetence over the last few weeks |
The latest interim results suggest that the efforts of newish CEO Jenny Winter appearing to be bearing fruit, despite the short term disruptions.
Revenue declined 4.4% to £34.5m due to the impact of the pandemic, with largest product category of Companion Animals seeing a 10.6% decline to £21.2m and Production animals seeing 13.1% growth to £10.5m. Equine and other declined 10% to £2.7m.
More on the Investor's Champion website. |
 The full statement from the auditor's report - Hedging opinion (imo)
Material uncertainty related to
going concern – Group and Parent
Company
In forming our opinion on the financial
statements, which is not modified, we have
considered the adequacy of the disclosure
made in note 3 to the group financial
statements and note 1 to the parent
company’s financial statements concerning
the group’s and parent company’s ability to
continue as a going concern.
The Group’s forecast cash flows contain
assumptions over revenue, profitability
and cash generation. These forecasts have
been stress-tested for severe but plausible
scenarios that could impact the Group.
These show that in a more prolonged severe
downturn there may be a potential breach
of the leverage covenant for the Group’s
borrowing facility. If such a breach were
to occur the Group would need to obtain
a covenant relaxation or waiver from the
Group’s banking syndicate. This condition,
along with the other matters explained in
note 3 to the financial statements, indicates
the existence of a material uncertainty which
may cast significant doubt about the group’s
and parent company’s ability to continue as
a going concern. The financial statements
do not include the adjustments that would
result if the group and parent company were
unable to continue as a going concern.
Explanation of material uncertainty
Management and the Board considered the
potential impact of COVID-19 on the current
and future operations of the business. In
doing so, management focused on the
Group’s ability to continue as a going concern
by performing a detailed bottom-up analysis
of the impact of COVID-19 on revenue,
EBITDA and cashflows. Management made
estimates and judgements that are critical to
the outcome of these considerations. Three
scenarios were modelled – a new base case
and two further downside scenarios. This
analysis has been used in conjunction with
an assessment of the Group’s liquidity and
consideration of loan covenants.
Audit procedures performed
In assessing management’s consideration
of the potential impact of COVID-19, we
undertook the following procedures:
• We obtained management’s board
report that details the Group’s
assessment and conclusions with respect
to their ability to continue as a going
concern;
• We assessed the initial 2020 (preCOVID-19) budget as well as the new
base case forecast and two further
downside scenarios (each of which factor
in COVID-19 overlays);
• We confirmed that the initial 2020 (pre
COVID-19) budget was board approved.
In addition, we evaluated the historical
accuracy of the budgeting process to
assess the reliability of the data;
• In relation to the COVID-19 overlays, we
held discussions with management to
understand and challenge the rationale
behind the assumptions made, using our
knowledge of the business and industry;
• We reviewed the latest trading results for
the year to date in 2020 and compared
to management’s original budget,
FY19 actuals and revised forecasts, and
considered the impact of these actual
results on the future forecast period;
• We understood the mitigating actions
taken by management, including
suspending the final dividend payment;
• We reviewed management’s sensitivity
scenarios and we challenged
management to run further downside
scenarios in order to assess the possible
impact of headroom against their
borrowing facilities; and
• We reviewed the disclosures included
within the Annual Report and consider
these to be appropriate. |
Hello Everyone,Not sure if you have seen this, re Animalcare."Animalcare Group plc Auditor Raises 'Going Concern' DoubtAnimalcare Group plc filed its Annual on Jun 09, 2020 for the period ending Dec 31, 2019. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern."CheersMartin |
Tipped by Chris Boxall of FAM today. |
Perking up on some chunky volume |
i remember this one - i was looking at it pre-merger and never really understood why the management went for it. Guess I will look in after the results at the end of the month but the text from the statements doesn't fit with the figures. Having worked in a bank turnaround story for 10 years - I've seen many new CEOs come in and kitchen sink the first set of results and we'll have to see if Jenny Winter does the same. |
that is one nasty looking chart |
time this one started to lose the "dog status" if you know what i mean - welcoming all new posters for comments - good luck all |
i have set up a new thread that may (?) help the price (?) if nothing else ; this one is 11 years old - welcome to see posters over there - see if this dog can start to turn |
New CEO in Jenny Winter recently appointed has an opportunity to finally put this business back on track.
Hideous journey to date with frankly pure value destruction further to the Ecuphar merger.
An AIM 2017 transaction award for this deal leaves somewhat of a nasty taste in the mouth - the chart says it all.
However, profitable and growth markets with a renewed focus on higher margins part of strategy.
Results at the end of April will hopefully show that green shoots are visible.
One to watch in my view.
DYOR and good luck to all investors new and existing. |
2019 AGM
25/06/2019
2018 Year End Preliminary Announcement
30/04/2019 |
Hmm what is going on here? I was looking at this stock in 2017 as it was held by some AIM VCTs I was look into. Then this transaction went ahead and put my off as it felt like empire building. What do people think?
A slight aside - I still think it's strange this is the front of their investors webpage. Now valued at 85m...
'Animalcare Group plc wins AIM Transaction of the Year Award at the AIM Awards 2017
We are delighted to announce that Animalcare Group plc has won AIM Transaction of the Year Award at the AIM Awards 2017. The award is given to a Company that “has been transformed by a single financial or commercial transaction during the period under review and thereby creating significant shareholder value.”
The award following the acquisition of Ecuphar NV, a European animal health company that develops and sells veterinary pharmaceutical products. The deal has transformed the company creating a specialist pan-European animal health company with strong leadership in our chosen niches, supported by attractive and complementary market drivers. Animalcare and Ecuphar are highly complementary businesses, in particular with regard to our respective geographic markets, product portfolios and new product development pipelines, and combined will provide enhanced scale and capabilities. The enlarged group is now a growing, highly cash generative, dividend paying company with a solid pipeline of new products and now has a stock market value of the Company of around £200m.
The AIM Awards, now it its 22nd year, brings together quoted companies, entrepreneurs across the AIM market to recognise their achievements, growth in the last twelve months. The dinner attracts over 1,300 guests, ranging from NOMADS and brokers to accountants, lawyers, IR and financial PR professionals.' |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
